| Mar 4 |
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
|
| Feb 12 |
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
|
| Feb 7 |
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
| Jan 30 |
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
|
| Jan 25 |
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
|
| Jan 22 |
Cellectar stock climbs 8% on results for CNS malignancy therapy
|
| Jan 22 |
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
|
| Jan 16 |
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
|
| Jan 12 |
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
|
| Jan 11 |
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
|
